Inflammation and Atherosclerosis - The End of a Controversy
Does inflammation matter in coronary artery disease? Is it a driving force in atherosclerosis, or merely an epiphenomenon? And is there space for novel therapies besides those targeting cholesterol? The CANTOS trial, which was presented at the European Society of Cardiology meeting in Barcelona a few weeks ago provides answers to these important questions. Indeed, the results of this trial open up a new avenue for cardiovascular prevention.
- Received September 4, 2017.
- Revision received September 9, 2017.
- Accepted September 11, 2017.